Sugi Predict
/ Targets
/ CDK2AP2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to CDK2AP2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) |
PHASE3 | COMPLETED |
| Effect of Silymarin in Metastatic Colorectal Cancer Patients |
PHASE3 | UNKNOWN |
| Avelumab, Palbociclib and Axitinib in Advanced RCC |
PHASE2 | WITHDRAWN |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
PHASE2 | COMPLETED |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 |
PHASE2 | RECRUITING |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations |
PHASE2 | COMPLETED |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Abemaciclib + Pembrolizumab In Glioblastoma |
PHASE2 | WITHDRAWN |
| Abemaciclib With or Without Atezolizumab for mCRPC |
PHASE2 | COMPLETED |
| Study of AVZO-021 in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer |
PHASE2 | WITHDRAWN |
| Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Selective Treatment According to Molecular Subtype of Prostate Cancer |
PHASE2 | UNKNOWN |
| Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression |
PHASE2 | COMPLETED |
| An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. |
PHASE1/PHASE2 | COMPLETED |
| Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
PHASE2 | COMPLETED |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer |
PHASE2 | RECRUITING |
| Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. |
PHASE2 | COMPLETED |
| Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer |
PHASE2 | UNKNOWN |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms |
PHASE1 | COMPLETED |
| Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma |
PHASE1 | WITHDRAWN |
| TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
PHASE1 | RECRUITING |
| The Relation of Microtubule-Associated Protein 2 and Cell Migration |
nan | UNKNOWN |
| Genetic Analysis of Familial Melanoma |
nan | COMPLETED |
| Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a CDK2AP2 binder may also engage these)